ZNTL लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 108098 min ago

@ $11.35

जारी किया गया: 14 Feb 2024 @ 20:00

वापसी: -2.82%

पिछला सिग्नल: Feb 13 - 20:00

पिछला सिग्नल: खरीदें

वापसी: 3.37 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 21:38):

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...

Stats
आज की मात्रा	89 941.00
औसत मात्रा	829 708
बाजार मूल्य	782.69M
EPS	$0 ( 2024-03-06 )
अगली कमाई की तारीख	( $-0.850 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.47
ATR14	$0.0270 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Vultaggio Vincent	Sell	0	Common Stock
2024-04-05	Vultaggio Vincent	Sell	12 500	Stock Option (Right to Buy)
2024-04-05	Vultaggio Vincent	Sell	10 000	Stock Option (Right to Buy)
2024-04-05	Vultaggio Vincent	Sell	6 875	Stock Option (Right to Buy)
2024-04-05	Vultaggio Vincent	Sell	2 750	Stock Option (Right to Buy)

INSIDER POWER
85.13
Last 97 transactions
Buy: 9 826 125 \| Sell: 711 798

मात्रा सहसंबंध

लंबा: -0.33 (neutral)

छोटा: -0.82 (strong negative)

Signal:(53.871) Neutral

Zentalis Pharmaceuticals सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध
RAVN	-0.813

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Zentalis Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र

0.51
( weak )

0.37
( neutral )

0.00
( neutral )

0.51
( weak )

0.45
( neutral )

0.20
( neutral )

Zentalis Pharmaceuticals वित्तीय

Annual	2023
राजस्व:	$0
सकल लाभ:	$-1.39M (0.00 %)
EPS:	$-4.47

FY	2023
राजस्व:	$0
सकल लाभ:	$-1.39M (0.00 %)
EPS:	$-4.47

FY	2022
राजस्व:	$0
सकल लाभ:	$-1.43M (0.00 %)
EPS:	$-4.18

FY	2021
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-5.65

Financial Reports:

No articles found.

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.